SCHEMBL781008

SCHEMBL781008

CON(C)C(=O)c1cccnc1F

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NAPRT Q6XQN6 2/20 0.56
MLYCD O95822 1/20 0.39
TRPM8 Q7Z2W7 2/20 0.39
TDP1 Q9NUW8 2/20 0.38
KDM4E B2RXH2 2/20 0.38
ALDH1A1 P00352 2/20 0.37
NPSR1 Q6W5P4 2/20 0.37
CYP3A4 P08684 1/20 0.37
MAPT P10636 1/20 0.37
ALOX15 P16050 1/20 0.37
TSHR P16473 1/20 0.37
BLM P54132 1/20 0.37
AGER Q15109 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
KMT2A Q03164 1/20 0.37
LMNA P02545 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
P2RX7 Q99572 1/20 0.36
POLB P06746 1/20 0.36
PDE4B Q07343 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1092652 0.83 TRPM8 (0.42) NAPRTMLYCDTRPM8TDP1KDM4E
SCHEMBL307472 0.83 P2RX7 (0.50) NAPRTTRPM8TDP1KDM4EALDH1A1
SCHEMBL1034880 0.82 NAPRT (0.63) NAPRTTDP1KDM4EALDH1A1NPSR1
SCHEMBL257468 0.82 LMNA (0.54) TDP1L3MBTL1KMT2ALMNASMN1; SMN2
SCHEMBL16345329 0.82 TRIM24 (0.40) NAPRTMLYCDTRPM8TDP1KDM4E
SCHEMBL29865799 0.82 LMNA (0.54) TDP1L3MBTL1KMT2ALMNASMN1; SMN2
SCHEMBL306737 0.82 POLB (0.45) NAPRTTDP1ALDH1A1NPSR1MAPT
SCHEMBL29999839 0.82 TRIM24 (0.40) NAPRTMLYCDTRPM8TDP1KDM4E
SCHEMBL1447353 0.81 HCRTR1 (0.45) NAPRTMLYCDTDP1KDM4ECYP3A4
SCHEMBL25298982 0.80 MLYCD (0.40) NAPRTMLYCDTDP1KDM4ECYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 100 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240174663-A1 PYRIMIDINE OR PYRIDINE DERIVATIVES USEFUL AS HCN2 MODULATORS KING'S COLLEGE LONDON (GB) 2024-05-30 US disclosed
EP-4301751-A1 PYRIMIDINE OR PYRIDINE DERIVATES USEFUL AS HCN2 MODULATORS King's College London (GB) 2024-01-10 EP disclosed
US-20230416256-A1 SMALL MOLECULE INHIBITORS OF NF-kB INDUCING KINASE JANSSEN PHARAMCEUTICA NV (BE) 2023-12-28 US disclosed
EP-4244224-A1 SMALL MOLECULE INHIBITORS OF NF-KB INDUCING KINASE JANSSEN Pharmaceutica NV (BE) 2023-09-20 EP disclosed
WO-2022185057-A1 PYRIMIDINE OR PYRIDINE DERIVATES USEFUL AS HCN2 MODULATORS KING'S COLLEGE LONDON (GB) 2022-09-09 WO disclosed
WO-2022104348-A1 SMALL MOLECULE INHIBITORS OF NF-KB INDUCING KINASE JANSSEN PHARMACEUTICA NV (BE) 2022-05-19 WO disclosed
EP-2528917-B1 PYRAZOLOPYRIDINES USEFUL FOR THE TREATMENT OF AUTOIMMUNE, INFLAMMATORY OR (HYPER)PROLIFERATIVE DISEASES VERTEX PHARMA (US) 2016-10-19 EP disclosed
EP-2528917-B1 PYRAZOLOPYRIDINES USEFUL FOR THE TREATMENT OF AUTOIMMUNE, INFLAMMATORY OR (HYPER)PROLIFERATIVE DISEASES VERTEX PHARMA (US) 2016-10-19 EP disclosed
EP-2318408-B1 TRI-CYCLIC PYRAZOLOPYRIDINE KINASE INHIBITORS VERTEX PHARMA (US) 2016-02-17 EP disclosed
EP-2318408-B1 TRI-CYCLIC PYRAZOLOPYRIDINE KINASE INHIBITORS VERTEX PHARMA (US) 2016-02-17 EP disclosed
WO-2010011772-A2 TRI-CYCLIC PYRAZOLOPYRIDINE KINASE INHIBITORS VERTEX PHARMACEUTICALS INCORPORATED (US) 2010-01-28 WO disclosed
EP-2121613-A2 2-AMINOPYRIDINE DERIVATIVES USEFUL AS KINASE INHIBITORS Vertex Pharmaceuticals, Inc. (US) 2009-11-25 EP disclosed
US-20090124602-A1 KINASE INHIBITORS VERTEX PHARMACEUTICALS INCORPORATED 2009-05-14 US disclosed
US-20090124602-A1 KINASE INHIBITORS VERTEX PHARMACEUTICALS INCORPORATED 2009-05-14 US disclosed
US-20090124602-A1 KINASE INHIBITORS VERTEX PHARMACEUTICALS INCORPORATED 2009-05-14 US disclosed
WO-2009035855-A2 NOVEL USES OF HALOGENATED ALKYL SULFONAMIDES H. LUNDBECK A/S (DK) 2009-03-19 WO disclosed
WO-2008094992-A2 2-AMINOPYRIDINE DERIVATIVES USEFUL AS KINASE INHIBITORS VERTEX PHARMACEUTICALS INCORPORATED (US) 2008-08-07 WO disclosed
WO-2008094992-A2 2-AMINOPYRIDINE DERIVATIVES USEFUL AS KINASE INHIBITORS VERTEX PHARMACEUTICALS INCORPORATED (US) 2008-08-07 WO disclosed
WO-2007103295-A2 HALOGENATED SULFONAMIDE DERIVATIVES H. LUNDBECK A/S (DK) 2007-09-13 WO disclosed
US-20070213376-A1 Halogenated sulfonamide derivatives H. LUNDBECK A/S (DK) 2007-09-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070213376-A1 Halogenated sulfonamide derivatives NPY5R, NPY2R, SSTR5 NAPRT 2817/4885MLYCD 1911/4885TRPM8 1470/4885
US-20090124602-A1 KINASE INHIBITORS MAP3K20, MAP3K1, MAP3K6 NAPRT 1808/4885MLYCD 3167/4885TRPM8 3155/4885
US-20230416256-A1 SMALL MOLECULE INHIBITORS OF NF-kB INDUCING KINASE NFKBIA, IKBKB, NFRKB NAPRT 1193/4885MLYCD 827/4885TRPM8 3088/4885
US-20240174663-A1 PYRIMIDINE OR PYRIDINE DERIVATIVES USEFUL AS HCN2 MODULATORS HCN2, HCN1, HCN3 NAPRT 342/4885MLYCD 2821/4885TRPM8 42/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.